INS and Parkinson disease: On the other hand, the alterations of insulin signaling exacerbate PD clinical-pathological symptoms, enhancing dopaminergic degeneration and worsening disease progression and, in parallel, both motor and cognitive decline (Papapetropoulos et al., 2004).